372
Participants
Start Date
November 30, 2012
Primary Completion Date
March 31, 2017
Study Completion Date
February 17, 2021
KW-0761
1.0 mg/kg weekly x 4 in cycle 1 then every other week until progression
Vorinostat
Westmead Hospital, Westmead
Parkville Cancer Clinical Trials Unit, Melbourne
Royal Adelaide Hospital, Adelaide
Flinders Medical Centre, Bedford Park
Aarhus University Hospital, Aarhus
University Hospital Zurich, Zurich
Columbia Presbyterian, New York
Memorial Sloan Kettering Cancer Center, New York
Universita degli Studi di Torino, Turin
Universal Dermatology, PLLC, Fairport
University of Rochester School of Medicine, Rochester
University of Pittsburgh School of Medicine, Pittsburgh
University of Pennsylvania, Philadelphia
Thomas Jefferson University, Philadelphia
Wake Forest Baptist Medical Center, Winston-Salem
Hospital Universitario 12 de Octubre, Madrid
The Winship Cancer Institute (Emory University), Atlanta
CHU Bordeaux - Hopital Haut-Leveque, Pessac
H. Lee Moffitt Cancer Center, Tampa
University of Alabama - Birmingham, Birmingham
Hospital Universitario de Salamanca, Salamanca
Vanderbilt University Medical Center, Nashville
Institute of Hematology and Oncology Lorenzo e Ariosto Seràgnoli, University of Bologna, Bologna
Ohio State University, Columbus
CHU de Nantes, Nantes
University Hospitals Cleveland Medical Center, Cleveland
Indiana University, Indianapolis
University of Michigan, Ann Arbor
University Hospital Muenster, Münster
Medical College of Wisconsin, Milwaukee
Northwestern University, Chicago
Washington University School of Medicine, St Louis
University of Kansas Cancer Center, Westwood
Centre Hospitalier Lyon Sud, Pierre-Bénite
Tulane University Medical Center, New Orleans
Hôpital Saint Louis, Paris
M.D.Anderson Cancer Center, Houston
University of Colorado, Aurora
Huntsman Cancer Institute, Salt Lake City
Banner MD Anderson, Gilbert
UCLA Medical Center, Los Angeles
City of Hope National Medical Center, Duarte
Stanford Medical Center, Stanford
University of Washington, Seattle
Yale University School of Medicine - Yale Cancer Center, New Haven
Massachusetts General Hospital, Boston
Boston Medical Center, Department of Medicine, Section of Hem/Onc, Boston
Dana Farber Cancer Institute, Boston
Dartmouth Hitchcock Medical Center, Lebanon
University Medical Centre Mannheim, Mannheim
Nagoya City University Hospital, Nagoya
Fukushima Medical University Hospital, Fukushima
Gunma University Hospital, Maebashi
Hiroshima University Hospital, Hiroshima
Asahikawa Medical University Hospital, Asahikawa
Imamura Bun-in Hospital, Kagoshima
Yokohama City University Hospital, Yokohama
Kochi Medical School Hospital, Nankoku-shi
Mie University Hospital, Tsu
Tohoku University Hospital, Sendai
Shinshu University Hospital, Matsumoto-shi
Okayama University Hospital, Okayama
Kansai Medical University Hospital, Hirakata-shi
Osaka University Hospital, Suita-shi
Hamamatsu University Hospital, Hamamatsu
The University of Tokyo Hospital, Bunkyo-ku
National Cancer Center Hospital, Chuo-ku
Tokyo Metropolitan Tama Medical Center, Fuchu-shi
Japanese Foundation for Cancer Research, Koto-ku
Leiden University Medical Center - Leids Universitair Medisch Centrum (LUMC), Leiden
The Christie Hospital Foundation NHS Trust, Manchester
University Hospital Birmingham, Birmingham
Guys & St. Thomas NHS Trust, London
Lead Sponsor
Kyowa Kirin, Inc.
INDUSTRY